Milnacipran Glenmark (Milnacipran Hydrochloride)

Milnacipran blocks the reuptake of the neurotransmitters serotonin and norepinephrine at neuronal synapses. By preventing their reabsorption, it raises their extracellular concentrations, which enhances mood regulation and reduces depressive symptoms.

The dosage of milnacipran is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength, frequency, and duration of therapy.

Safety data for milnacipran in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative treatment options when treating pregnant or nursing individuals.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Milnacipran is an SNRI, offering dual inhibition of serotonin and norepinephrine reuptake, whereas SSRIs target only serotonin. This broader mechanism may provide additional benefits for certain patients, but the choice of therapy depends on individual response, side‑effect profile, and clinical judgment.

Milnacipran Glenmark tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight, and extreme temperatures to maintain product stability.

The product is supplied as oral tablets intended for swallowing with water. Patients should follow the dosing schedule prescribed by their healthcare professional and should not alter the regimen without medical advice.

Serious risks include elevated blood pressure, serotonin syndrome when combined with other serotonergic drugs, and the emergence of suicidal thoughts, especially during early treatment. Prompt medical attention is required if any of these events occur.

Milnacipran is contraindicated in patients taking monoamine oxidase inhibitors, those with uncontrolled hypertension, severe hepatic impairment, or a known hypersensitivity to milnacipran or any of its excipients. Clinicians should assess each patient’s medical history before initiating therapy.